Edesa jumped more than 44% on heavy volume after licensing its ARDS drug candidate paridiprubart to Japan’s KYORIN Pharmaceutical for $12 million upfront and up to about $134 million in…
Tag:
Edesa jumped more than 44% on heavy volume after licensing its ARDS drug candidate paridiprubart to Japan’s KYORIN Pharmaceutical for $12 million upfront and up to about $134 million in…
Welcome to AI Investor Picks, your trusted source for investment insights, financial strategies, and business opportunities. We are dedicated to providing cutting-edge information and analysis on a wide range of investment topics, including stocks, cryptocurrency, real estate, finance, and much more.
© 2025 AI Investor Picks – All Rights Reserved